ArticleFrontiers in cell and developmental biology2026
Serum exosomal DDX17 in the diagnosis and action mechanism of hepatocellular carcinoma.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to explore DDX17 protein expression as a diagnostic biomarker of hepatocellular carcinoma (HCC) and its roles in the occurrence and development of HCC. Methods: The proteomics sequencing method was applied to study nine samples of exosomes separated from HCC tissues and corresponding normal non-cancerous tissues. We also performed nanoflow cytometry analysis of DDX17 expression in serum-derived exosomes from 102 HCC patients, 58 persons with liver cirrhosis (LC), and 80 healthy donors (HDs). The feasibility of DDX17 as a diagnostic and prognostic biomarker was evaluated using receiver operating characteristic (ROC) curves. The effects of HCC-derived exosomal DDX17 on LX-2 cell proliferation, migration, and epithelial-mesenchymal transition (EMT) were evaluated through cell proliferation, colony formation, wound healing, transwell migration, and western blotting assays. Results: We found that exosomes produced by HCC cells had much higher levels of DDX17 than those produced by the adjacent non-cancerous tissues. ROC analysis showed that exosomal DDX17 has a strong ability to distinguish HCC with both high sensitivity and high specificity. If the exosomal DDX17 result is negative, then we expect it to be a new kind of diagnostic biomarker. Moreover, we observed that DDX17-positive exosome subtypes isolated from the HepG2 cell line increased cell proliferation, migration, invasion, and EMT in the LX-2 cell line. Conclusion: DDX17-positive exosomes are potential diagnostic biomarkers of HCC and are expected to promote tumor growth, migration, invasion, and EMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.